Salvestrols: A new perspective in nutritional research

Journal of Orthomolecular Medicine

Volumn 22, Issue 1, 2007, Pages 39-47

  Tan, Hoon L ^a   Butler, Paul C ^b   Burke, M Danny ^b   Potter, Gerard A ^b  

^a Nature's Defence Investments   (United Kingdom)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

CYP1B1; Cytochrome P450; Natural anticancer prodrug; Salvestrols

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450; CYTOCHROME P450 2B1; ICOSANOID; PHENOBARBITAL; PHYTOALEXIN; PRODRUG; RESVERATROL; SALVESTROL DERIVATIVE; STEROID HORMONE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; CYTOTOXICITY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUTRITIONAL SCIENCE;

EID: 34147126437     PISSN: 03170209     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (71)

1. Hintz MJ: Mechanism of Electron-Transfer from Reduced Putidaredoxin to Cytochrome-P-450. Federation Proc, 1981; 40(6): 1662-1662.
2. Hintz MJ, Peterson, JA: The Kinetics of Reduction of Cytochrome-P-450cam by Reduced Putidaredoxin. J Biol Chem, 1981; 256(13): 6721-6728.
3. Nadler SG, Strobel HW: Role of Electrostatic Interactions in the Reaction of Nadph-Cytochrome P-450 Reductase with Cytochromes P-450. Arch Biochem Biophys, 1988; 261(2): 418-429.
4. Voznesensky, AI Schenkman, JB: Electron-Transfer between Nadph-Cytochrome-P-450 Reductase (Red) and Cytochrome-P-450 (Cy-p2b4) Does Not Involve Complimentary Charge Pairing. Faseb J, 1992; 6(1): A320-A320.
5. Voznesensky, AI Schenkman JB: The cytochrome-p450 2b4-nadph cytochrome-p450 reductase electron-transfer complex is not formed by charge-pairing. J Biol Chem, 1992; 267(21): 14669-14676.
6. Shen S, Strobel HW: Role of Lysine and Arginine Residues of Cytochrome-P450 in the Interaction between Cytochrome-P4502b1 and Nadph-Cytochrome-P450 Reductase. Faseb J, 1993; 7(7): A1169-A1169.
7. Hayes CL, Spink DC, Spink, BC, et al: 17b-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad of Sci USA, 1996; 93: 9776-9781.
8. Badawi, A F, Cavalieri, E L, Rogan, E G: Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16a-hydroxylation of 17b-estradiol. Metabol-Clin Exper, 2001; 50(9): 1001-1003.
9. Liehr J, Ulubelen A, Strobel, H: Cytochrome P450-mediated redox cycling of estrogens. J Biol Chem, 1986; 261(36): 16865-16870.
10. Liehr JG: Genotoxic Effects of Estrogens. Mutation Res, 1990; 238(3): 269-276.
11. Liehr JG, Roy D: Free-Radical Generation by Redox Cycling of Estrogens. Free Rad Biol Med, 1990; 8(4): 415-423.
12. Cavalieri EL, Stack DE, Devanesan PD, et al: Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad of Sci USA, 1997; 94(20): 10937-10942.
13. Cavalieri EL, Devanesan P, Bosland MC, et al: Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. Carcinogen, 2002; 23(2): 329-333.
14. Yaffe SJ: Presence of a Monooxygenase System in Human Fetal Liver Microsomes. Life Sci Pt-2 Biochem Genet Molec Biol, 1970; 9(20): 1189-&.
15. Stoilov I, Akarsu AN, Sarfarazi M: Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Human Molec Genet, 1997; 6(4): 641-647.
16. Guengerich FP, Shimada T: Oxidation of Toxic and Carcinogenic Chemicals by Human Cytochrome P450 Enzymes. Chem Res Toxicol, 1991; 4(4): 391-407.
17. Shimada T, Hayes CL, Yamazaki H, et al: Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Canc Res, 1996; 56(13): 2979-2984.
18. Crofts FG, Sutter, TR, Strickland PT: Metabolism of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. Carcinogenesis, 1998; 19(11): 1969-1973.
19. Kim JH, Stansbury KH, Walker NJ, et al: Metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis, 1998; 19(10): 1847-1853.
20. Turesky RJ, Guengerich FP, Guillouzo A, et al: Metabolism of heterocyclic aromatic amines by human hepatocytes and cytochrome P4501A2. Mutation Res-Fund Molec Mech Mutagen, 2002; 506: 187-195.
21. Gonzalez FJ, Nebert DW: Evolution of the P450-Gene Superfamily - Animal Plant Warfare, Molecular Drive and Human Genetic-Differences in Drug Oxidation. Trend Genet, 1990; 6(6): 182-186.
22. Le Bail JC, Varnat F, Nicolas JC, et al: Estrogenic and antiproliferative activities on MCF7 human breast cancer cells by flavonoids. Canc Lett, 1998; 130(1-2): 209-216.
23. Le Bail JC, Laroche T, Marre-Fournier F, et al: Aromatase and 17b-hydroxysteroid dehydrogenase inhibition by flavonoids. Canc Lett, 1998; 133(1): 101-106.
24. Le Bail JC, Champavier Y, Chulia AJ et al: Effects of phytoestrogens on aromatase, 3b- and 17b-hydroxysteroid dehydrogenase activities and human breast cancer cells. Life Sci, 2000; 66(14): 1281-1291.
25. Youdim KA, Dobbie MS, Kuhnle G, et al: Interaction between flavonoids and the blood-brain barrier: in vitro studies. J Neurochemistry, 2003; 85(1): 180-192.
26. Lewis DFV: Guide to Cytochrome P450- Structure and Function. 2001, London and New York: Taylor & Francis.
27. Nebert DW, Adesnik M, Coon MJ, et al: The P450 Gene Superfamily - Recommended Nomenclature. DNA, 1987; 6(1): 1-11.
28. http://drnelson.utmem.edu/CytochromeP450. html, Cytochrome P450 Homepage. 2004, Nelson, DR
29. Gotoh O, Fujii-Kuriyama Y: Evolution, structure and gene regulation of cytochrome P450. Frontiers in Biotrans, 1989; 1: 195-243.
30. Creighton TE, Proteins: Structure and Molecular Properties. 1993, New York: Freeman.
31. Tajima F, Nei M: Estimation of Evolutionary Distance between Nucleotide- Sequences. Mol Biol Evol, 1984; 1(3): 269-285.
32. Nelson DR, Strobel HW: Evolution of Cytochrome-P-450 Proteins. Molec Biol Evol, 1987; 4(6): 572-593.
33. Nebert DW, Nelson DR, Coon MJ, et al: The P450 Superfamily - Update on New Sequences, Gene-Mapping, and Recommended Nomenclature. DNA Cell Biol, 1991; 10(1): 1-14.
34. Nelson DR: Metazoan cytochrome P450 evolution. Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicol Endocrinol, 1998; 121(1-3): 15-22.
35. Cleaves HJ, Miller SL: Oceanic protection of prebiotic organic compounds from UV radiation. Proc Natl Acad of Sci USA, 1998; 95(13): 7260-7263.
36. Wickramashighe RH, Villee CA: Early role during chemical evolution for cytochrome P450 in oxygen detoxification. Nature, 1975; 256(5517): 509-510.
37. Hattori K, Krouse HR, Campbell FA: The Start of Sulfur Oxidation in Continental Environments - About 2.2x10(9) Years Ago. Science, 1983; 221(4610): 549-551.
38. Canfield, DE, Teske, A: Late Proterozoic rise in atmospheric oxygen concentration inferred from phylogenetic and sulphur-isotope studies. Nature, 1996; 382(6587): 127-132.
39. Margulis L, Segan D: What is Life? 1995, London: Weidenfeld & Nicolson.
40. Knoll AH: The Early Evolution of Eukaryotes-a Geological Perspective. Science, 1992; 256(5057): 622-627.
41. Lewis, DFV, Watson, E, Lake, BG: Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. Mutation Res-Reviews in Mutation Res, 1998; 410(3): 245-270.
42. Porter TD, Coon, MJ: Cytochrome-P-450 - Multiplicity of Isoforms, Substrates, and Catalytic and Regulatory Mechanisms. J Biol Chem, 1991; 266(21): 13469-13472.
43. Harland WB, Armstrong RL, Craig LE, et al, A Geological Time Scale. 1989, Cambridge: Cambridge University Press.
44. Pottenger LH, Jefcoate CR: Characterization of a Novel Cytochrome P450 from the Transformable Cell-Line, C3h-10t1/2. Carcinogen, 1990; 11(2): 321-327.
45. Sutter, T R, Guzman, K, Dold, K M, et al: Targets for Dioxin - Genes for Plasminogen-Activator Inhibitor- 2 and Interleukin-1-Beta. Science, 1991; 254(5030): 415-418.
46. Murray, G I, Taylor, MC, McFadyen, MCE, et al: Tumor-specific expression of cytochrome P450 CYP1B1. Canc Res, 1997; 57(14): 3026-3031.
47. McFadyen, MC, Breeman, S, Payne, S, et al: Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochemistry & Cytochemistry, 1999; 47: 1457-1464.
48. Gibson, P, Gill, JH, Khan, PA, et al: Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: Implications for drug development. Molecular Canc Therapeutics, 2003; 2(6): 527-534.
49. McFadyen, MCE, Melvin, WT, Murray GI: Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Brit J Canc, 2004; 91(5): 966-971.
50. Maecker B, von Bergwelt-Baildon MS, Anderson KS, et al: Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clinical and Exper Immunology, 2005; 141(3): 558-562.
51. Tokizane T, Shiina H, Igawa M, et al: Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clinical Canc Res, 2005; 11(16): 5793-5801.
52. Oyama T, Morita M, Isse T, et al: Immunohistochemical evaluation of cytochrome P450 (CYP) and p53 in breast cancer. Frontiers Biosci, 2005; 10: 1156-1161.
53. Downie D, McFadyen MCE, Rooney PH, et al: Profiling cytochrome P450 expression in ovarian cancer: Identification of prognostic markers. Clinical Canc Res, 2005; 11(20): 7369-7375.
54. Carnell DM, Smith RE, Daley FM, et al: Target validation of cytochrome P450CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Intl J Radiation Oncol Biol Physics, 2004; 58(2): 500-509.
55. Stanley L, Ball M, Butler P, et al: Specific expression of cytochrome P450 CYP1B1 in cervical cancer. Drug Metab Rev, 2001; 33(2): S77.
56. Vadlamuri SV, Glover DD, Turner T, et al: Regiospecific expression of cytochrome P4501A1 and 1B1 in human uterine tissue. Canc Lett, 1998; 122(1-2): 143-150.
57. Hakkola J, Pasanen M, Pelkonen O, et al: Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcin, 1997; 18(2): 391-397.
58. Zhang, QY, Dunbar D, Ostrowska, A, et al: Characterization of human small intestinal cytochromes P450. Drug Metabol Disposit, 1999; 27(7): 804-809.
59. Rodriguez-Antona C, Donato MT, Pareja E, et al: Cytochrome P450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys, 2001; 393(2): 308-315.
60. Chang, TKH, Chen, J, Pillay, V, et al: Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver. Toxicological Sci, 2003; 71(1): 11-19.
61. Tsuchiya Y, Nakajima M, Takagi S, et al: MicroRNA regulates the expression of human cytochrome P4501B1. Canc Res, 2006; 66(18): 9090-9098.
62. Tang YM, Chen GF, Thompson PA, et al: Development of an antipeptide antibody that binds to the C-terminal region of human CYP1B1. Drug Metabol Disposit, 1999; 27: 274-280.
63. Muskhelishvili L, Thompson PA, Kusewitt DF, et al: In situ hybridization and immunohistochemical analysis of cytochrome P4501B1 expression in human normal tissues. J Histochem Cytoch 2001; 49(2): 229-236.
64. Potter GA, Patterson LH, Burke MD, et al: Hydroxylation activated prodrugs for cancer chemotherapy. PCT International Applications, 1999; WO99/40056.
65. Potter G, Patterson LH, Burke, MD, et al: Aromatic hydroxylation activated prodrugs. US Patent Application, 2000; 09/633,699.
66. Potter GA, Butler PC, Ruparelia KC, et al: DMU212: A novel CYP1B1 activated anticancer prodrug. Brit J Canc, 2002; 86: S117.
67. Sale S, Verschoyle RD, Boocock D, et al: Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′- tetramethoxystilbene. Brit J Canc, 2004; 90(3): 736-744.
68. Potter GA, Patterson LH, Wanogho E, et al: The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Brit J Canc, 2002; 86(5): 774-778.
69. Potter GA: The role of CYP1B1 as a tumour suppressor enzyme. Brit J Canc, 2002; 86: S12-S12.
70. Daniel O, Meier MS, Schlatter J, et al: Selected phenolic compounds in cultivated plants: Ecologic functions, health implications, and modulation by pesticides. Environ Health Perspect, 1999; 107: 109-114.
71. Magee JB, Smith BJ, Rimando A: Resveratrol content of muscadine berries is affected by disease control spray program. Hortscience, 2002; 37(2): 358-361.1